Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D ...
Anixa Biosciences Initiates Dosing In Third Cohort In Its Ovarian Cancer CAR-T Clinical Trial
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif., Nov.